Tetraphase Pharmaceuticals (NASDAQ:TTPH) had its target price lowered by investment analysts at Stifel Nicolaus from $13.00 to $6.00 in a research report issued to clients and investors on Wednesday, Marketbeat reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price points to a potential upside of 179.07% from the stock’s current price.
A number of other equities research analysts also recently commented on TTPH. BMO Capital Markets downgraded Tetraphase Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price for the company. in a report on Wednesday. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $8.00 target price on shares of Tetraphase Pharmaceuticals in a report on Wednesday. HC Wainwright decreased their target price on Tetraphase Pharmaceuticals from $17.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday. BidaskClub downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Finally, B. Riley began coverage on Tetraphase Pharmaceuticals in a report on Monday. They set a “buy” rating and a $11.00 target price for the company. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. Tetraphase Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $10.39.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded down $3.28 during trading on Wednesday, hitting $2.15. The company had a trading volume of 16,861,522 shares, compared to its average volume of 461,216. Tetraphase Pharmaceuticals has a 12-month low of $2.10 and a 12-month high of $9.93. The firm has a market capitalization of $110.93, a P/E ratio of -0.75 and a beta of 2.28.
Hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in Tetraphase Pharmaceuticals during the third quarter valued at approximately $107,000. Brighton Jones LLC purchased a new position in Tetraphase Pharmaceuticals during the third quarter valued at approximately $108,000. Voya Investment Management LLC raised its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares in the last quarter. Virtu KCG Holdings LLC purchased a new position in Tetraphase Pharmaceuticals during the second quarter valued at approximately $147,000. Finally, Ameriprise Financial Inc. purchased a new position in Tetraphase Pharmaceuticals during the second quarter valued at approximately $162,000. Institutional investors own 58.28% of the company’s stock.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.